Q4 2023 Highlights
- Net revenue of $1.7
billion increased 6.1 percent year over year including the
14th week
- Comparable sales declined 0.9 percent year over year and
increased 4.4 percent on a two-year basis
- GAAP net loss of $22.6
million, or $(0.08) per share,
compared to GAAP net income of $32.7
million, or $0.12 per share in
the prior year
- Adjusted Net Income1 of $6.1
million, or $0.02 per share,
compared to $52.8 million, or
$0.20 per share in the prior
year
- Adjusted EBITDA1 of $105.3
million compared to $157.9 million in the prior
year
- Operating Cash Flow of $47.0
million compared to $136.5
million in the prior year
- Free Cash Flow1 of $(2.0) million compared to $70.6 million in the prior year
Full Year 2023 Highlights
- Net revenue of $6.3
billion increased 3.6 percent year over year including the
53rd week
- Comparable sales increased 1.8 percent year over year and
increased 6.3 percent on a two-year basis
- GAAP net loss of $1.3
billion, or $(4.78) per share,
which includes goodwill impairment of $1.2B, compared to GAAP net income of
$90.8 million, or $0.34 per share in the prior year
- Adjusted Net Income1 of $22.8
million, or $0.09 per
share, compared to $162.6
million, or $0.61 per
share in the prior year
- Adjusted EBITDA1 of $401.1
million compared to $530.8 million in the prior
year
- Operating Cash Flow of $215.7
million compared to $346.0
million in the prior year
- Free Cash Flow1 of $(9.9) million compared to $68.0 million in the prior year
SAN
DIEGO, March 13, 2024 /PRNewswire/ -- Petco
Health and Wellness Company, Inc. (Nasdaq: WOOF), a complete
partner in pet health and wellness, today announced its fourth
quarter and full year 2023 financial
results.
In the fourth quarter of 2023, Petco delivered net revenue of
$1.7 billion, up 6.1 percent versus
prior year, inclusive of a 14th week. On an as-reported
basis, the company's consumables business was up 8.8 percent versus
prior year, and services and other business was up 17.4 percent
versus prior year. Growth in the company's consumables and services
and other business was partially offset by the company's supplies
and companion animal business, down 1.4 percent versus prior year.
GAAP net loss in the fourth quarter of 2023 was $22.6 million or $(0.08) per share, compared to GAAP net income of
$32.7 million or $0.12 per share in the prior year. Adjusted Net
Income1 was $6.1 million
or $0.02 per share, compared to
$52.8 million or $0.20 per share in the prior year. Adjusted
EBITDA1 was $105.3 million
compared to $157.9 million in the
prior year.
For the full year 2023, Petco delivered net revenue of
$6.3 billion, up 3.6 percent versus
prior year, inclusive of a 53rd week. On an as-reported
basis, the company's consumables business was up 7.1 percent versus
prior year, and services and other business was up 21.9 percent
versus prior year. Growth in the company's consumables and services
and other business was partially offset by its supplies and
companion animal business, down 6.8 percent versus prior year. GAAP
net loss of $1.3 billion or
$(4.78) per share was inclusive of a
goodwill impairment of $1.2B,
compared to GAAP net income of $90.8
million or $0.34 per share in
the prior year. Adjusted Net Income1 was $22.8 million or $0.09 per share, compared to $162.6 million or $0.61 per share in the prior year. Adjusted
EBITDA1 was $401.1 million
compared to $530.8 million in the
prior year.
(1)
|
Adjusted EBITDA,
Adjusted Net Income, Adjusted Earnings Per Share ("Adjusted EPS"),
and Free Cash Flow are non-GAAP financial measures. See "Non-GAAP
Financial Measures" for additional information on non-GAAP
financial measures and a reconciliation to the most comparable GAAP
measures.
|
Given the change in leadership, the company is not providing
full year revenue, Adjusted EBITDA and Adjusted EPS guidance at
this time. Instead, the company is providing earnings guidance for
fiscal Q1. The company continues to provide interest, share count,
and capital expenditure expectations for the full year.
Fiscal Q1 2024 Outlook
For Fiscal Q1 2024, the company expects:
Metric*
|
FQ1 2024
Guidance
|
Net Revenue
|
~ $1.5
billion
|
Adjusted EBITDA
|
~ $70
million
|
Adjusted EPS
|
~ $(0.06)
|
Fiscal 2024 Outlook
For Fiscal 2024 (a 52-week year), the company expects:
Metric*
|
2024
Guidance,
YoY
|
Net interest
expense
|
~$145
million
|
Capital Expenditures
|
~$140
million
|
*Assumptions in the guidance include that economic conditions,
currency rates and the tax and regulatory landscape remain
generally consistent. For fiscal 2024, our guidance anticipates a
26 percent tax rate, and 272 million weighted average diluted share
count. Adjusted EBITDA and Adjusted EPS are non-GAAP
financial measures and have not been reconciled to the most
comparable GAAP outlook because it is not possible to do so without
unreasonable efforts due to the uncertainty and potential
variability of reconciling items, which are dependent on future
events and often outside of management's control and which could be
significant. Because such items cannot be reasonably predicted with
the level of precision required, we are unable to provide outlook
for the comparable GAAP measures. Forward-looking estimates of
Adjusted EBITDA and Adjusted EPS are made in a manner consistent
with the relevant definitions and assumptions noted herein and in
our filings with the Securities and Exchange Commission.
Earnings Conference Call Webcast Information:
Management will host an earnings conference call on March 13, 2024 at 8:00 AM
Eastern Time to discuss the company's financial results. The
conference call will be accessible through a live webcast.
Interested investors and other individuals can access the
webcast, earnings release, earnings presentation, infographic, and
earnings supplement via the company's investor relations page at
ir.petco.com. A replay of the webcast will be archived on the
company's investor relations page through March 27, 2024 until approximately 5:00 PM Eastern Time.
About Petco, The
Health + Wellness Co.:
Founded in 1965, Petco is a category-defining health and
wellness company focused on improving the lives of pets, pet
parents and our own Petco partners. We've consistently set new
standards in pet care while delivering comprehensive pet wellness
products, services and solutions, and creating communities that
deepen the pet-pet parent bond. We operate more than 1,500 pet care
centers across the U.S., Mexico
and Puerto Rico, which offer
merchandise, companion animals, grooming, training and a growing
network of on-site veterinary hospitals and mobile veterinary
clinics. Our complete pet health and wellness ecosystem is
accessible through our pet care centers and digitally at petco.com
and on the Petco app. In tandem with Petco Love, a life-changing
organization, we work with and support thousands of local animal
welfare groups across the country and, through in-store adoption
events, we've helped find homes for nearly 7 million animals.
Forward-Looking Statements:
This earnings release contains "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995 as contained in Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended, concerning expectations, beliefs, plans, objectives,
goals, strategies, future events or performance and underlying
assumptions and other statements that are not statements of
historical fact, including, but not limited to, statements
regarding our Q1 and fiscal year 2024 guidance, operational reset
of our business, our competitive positioning, profitability, cost
action plans and associated cost-savings. Such forward-looking
statements can generally be identified by the use of
forward-looking terms such as "believes," "expects," "may,"
"intends," "will," "shall," "should," "anticipates," "opportunity,"
"illustrative," or the negative thereof or other variations thereon
or comparable terminology. Although Petco believes that the
expectations and assumptions reflected in these statements are
reasonable, there can be no assurance that these expectations will
prove to be correct or that any forward-looking results will occur
or be realized. Nothing contained in this earnings release is, or
should be relied upon as, a promise or representation or warranty
as to any future matter, including any matter in respect of the
operations or business or financial condition of Petco. All
forward-looking statements are based on current expectations and
assumptions about future events that may or may not be correct or
necessarily take place and that are by their nature subject to
significant uncertainties and contingencies, many of which are
outside the control of Petco. Forward-looking statements are
subject to a number of risks, uncertainties and other factors that
could cause actual results or events to differ materially from the
potential results or events discussed in the forward-looking
statements, including, without limitation, those identified in this
earnings release as well as the following: (i) increased
competition (including from multi-channel retailers and e-Commerce
providers); (ii) reduced consumer demand for our products and/or
services; (iii) our reliance on key vendors; (iv) our ability to
attract and retain qualified employees; (v) risks arising from
statutory, regulatory and/or legal developments; (vi) macroeconomic
pressures in the markets in which we operate, including inflation
and prevailing interest rates; (vii) failure to effectively manage
our costs; (viii) our reliance on our information technology
systems; (ix) our ability to prevent or effectively respond to a
data privacy or security breach; (x) our ability to effectively
manage or integrate strategic ventures, alliances or acquisitions
and realize the anticipated benefits of such transactions; (xi)
economic or regulatory developments that might affect our ability
to provide attractive promotional financing; (xii) business
interruptions and other supply chain issues; (xiii) catastrophic
events, political tensions, conflicts and wars (such as the ongoing
conflict in Ukraine), health
crises, and pandemics; (xiv) our ability to maintain positive brand
perception and recognition; (xv) product safety and quality
concerns; (xvi) changes to labor or employment laws or regulations;
(xvii) our ability to effectively manage our real estate portfolio;
(xviii) constraints in the capital markets or our vendor credit
terms; (xix) changes in our credit ratings; (xx) impairments of the
carrying value of our goodwill and other intangible assets; (xxi)
our ability to successfully implement our operational adjustments,
achieve the expected benefits of our cost action plans and drive
improved profitability; and (xxii) the other risks, uncertainties
and other factors identified under "Risk Factors" and
elsewhere in Petco's Securities and Exchange Commission filings.
The occurrence of any such factors could significantly alter the
results set forth in these statements.
Petco cautions that the foregoing list of risks, uncertainties
and other factors is not complete, and forward-looking statements
speak only as of the date they are made. Petco undertakes no duty
to update publicly any such forward-looking statement, whether as a
result of new information, future events or otherwise, except as
may be required by applicable law, regulation or other competent
legal authority.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PETCO HEALTH AND
WELLNESS COMPANY, INC.
|
|
CONSOLIDATED
STATEMENTS OF OPERATIONS
|
|
(In thousands, except
per share amounts)
|
|
(Unaudited and subject
to reclassification)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14 Weeks
Ended
|
|
13 Weeks
Ended
|
|
|
|
53 Weeks
Ended
|
|
52 Weeks
Ended
|
|
|
|
|
|
February 3,
2024
|
|
January 28,
2023
|
|
Percent
Change
|
|
February 3,
2024
|
|
January 28,
2023
|
|
Percent
Change
|
|
Net sales:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Products
|
|
$ 1,420,713
|
|
$ 1,361,856
|
|
4 %
|
|
$ 5,273,710
|
|
$ 5,230,515
|
|
1 %
|
|
Services and
other
|
|
253,763
|
|
216,103
|
|
17 %
|
|
981,574
|
|
805,452
|
|
0
|
|
Total net
sales
|
|
1,674,476
|
|
1,577,959
|
|
6 %
|
|
6,255,284
|
|
6,035,967
|
|
4 %
|
|
Cost of
sales:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Products
|
|
903,156
|
|
805,938
|
|
12 %
|
|
3,269,628
|
|
3,035,249
|
|
8 %
|
|
Services and
other
|
|
164,972
|
|
144,742
|
|
14 %
|
|
631,821
|
|
573,611
|
|
10 %
|
|
Total cost of
sales
|
|
1,068,128
|
|
950,680
|
|
12 %
|
|
3,901,449
|
|
3,608,860
|
|
8 %
|
|
Gross
profit
|
|
606,348
|
|
627,279
|
|
(3 %)
|
|
2,353,835
|
|
2,427,107
|
|
(3 %)
|
|
Selling, general and
administrative expenses
|
|
606,182
|
|
549,719
|
|
10 %
|
|
2,311,625
|
|
2,201,548
|
|
5 %
|
|
Goodwill and
indefinite-lived intangible impairment
|
|
—
|
|
—
|
|
N/M
|
|
1,222,524
|
|
—
|
|
N/M
|
|
Operating income
(loss)
|
|
166
|
|
77,560
|
|
(100 %)
|
|
(1,180,314)
|
|
225,559
|
|
N/M
|
|
Interest
income
|
|
(326)
|
|
(745)
|
|
(56 %)
|
|
(3,405)
|
|
(1,032)
|
|
230 %
|
|
Interest
expense
|
|
39,658
|
|
32,882
|
|
21 %
|
|
150,909
|
|
101,643
|
|
48 %
|
|
Loss on extinguishment
and modification of debt
|
|
—
|
|
—
|
|
N/M
|
|
920
|
|
—
|
|
N/M
|
|
Other non-operating
loss (income)
|
|
—
|
|
3,298
|
|
(100 %)
|
|
(4,727)
|
|
12,667
|
|
N/M
|
|
(Loss) income before
income taxes and income from
equity method investees
|
|
(39,166)
|
|
42,125
|
|
N/M
|
|
(1,324,011)
|
|
112,281
|
|
N/M
|
|
Income tax (benefit)
expense
|
|
(10,435)
|
|
14,548
|
|
N/M
|
|
(27,613)
|
|
35,347
|
|
N/M
|
|
Income from equity
method investees
|
|
(6,156)
|
|
(5,155)
|
|
19 %
|
|
(16,188)
|
|
(12,976)
|
|
25 %
|
|
Net (loss)
income
|
|
(22,575)
|
|
32,732
|
|
N/M
|
|
(1,280,210)
|
|
89,910
|
|
N/M
|
|
Net loss attributable
to noncontrolling interest
|
|
—
|
|
—
|
|
N/M
|
|
—
|
|
(891)
|
|
(100 %)
|
|
Net (loss) income
attributable to Class A and B-1 common
stockholders
|
|
$
(22,575)
|
|
$
32,732
|
|
N/M
|
|
$
(1,280,210)
|
|
$
90,801
|
|
N/M
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income
per Class A and B-1 common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
(0.08)
|
|
$
0.12
|
|
N/M
|
|
$
(4.78)
|
|
$
0.34
|
|
N/M
|
|
Diluted
|
|
$
(0.08)
|
|
$
0.12
|
|
N/M
|
|
$
(4.78)
|
|
$
0.34
|
|
N/M
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
shares used in computing net (loss) income per Class A
and B-1 common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
268,615
|
|
265,918
|
|
1 %
|
|
267,549
|
|
265,522
|
|
1 %
|
|
Diluted
|
|
268,615
|
|
266,297
|
|
1 %
|
|
267,549
|
|
265,951
|
|
1 %
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PETCO HEALTH AND
WELLNESS COMPANY, INC.
|
CONSOLIDATED BALANCE
SHEETS
|
(In thousands, except
per share amounts)
|
(Unaudited and subject
to reclassification)
|
|
|
|
|
|
February
3,
2024
|
|
January
28,
2023
|
ASSETS
|
|
|
|
|
Current
assets:
|
|
|
|
|
Cash and cash
equivalents
|
|
$
125,428
|
|
$
201,901
|
Receivables, less
allowance for credit losses1
|
|
44,369
|
|
49,580
|
Merchandise
inventories, net
|
|
684,502
|
|
652,430
|
Prepaid
expenses
|
|
58,615
|
|
51,274
|
Other current
assets
|
|
38,830
|
|
60,809
|
Total current
assets
|
|
951,744
|
|
1,015,994
|
Fixed assets,
net
|
|
816,367
|
|
803,327
|
Operating lease
right-of-use assets
|
|
1,384,050
|
|
1,397,761
|
Goodwill
|
|
980,297
|
|
2,193,941
|
Trade name
|
|
1,025,000
|
|
1,025,000
|
Other long-term
assets
|
|
205,694
|
|
176,806
|
Total assets
|
|
$ 5,363,152
|
|
$ 6,612,829
|
LIABILITIES AND
EQUITY
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
Accounts payable and
book overdrafts
|
|
$
485,131
|
|
$
381,213
|
Accrued salaries and
employee benefits
|
|
101,265
|
|
89,929
|
Accrued expenses and
other liabilities
|
|
200,278
|
|
217,556
|
Current portion of
operating lease liabilities
|
|
310,507
|
|
309,766
|
Current portion of
long-term debt and other lease liabilities
|
|
15,962
|
|
22,794
|
Total current
liabilities
|
|
1,113,143
|
|
1,021,258
|
Senior secured credit
facilities, net, excluding current portion
|
|
1,576,223
|
|
1,628,331
|
Operating lease
liabilities, excluding current portion
|
|
1,116,615
|
|
1,148,155
|
Deferred taxes,
net
|
|
251,629
|
|
303,121
|
Other long-term
liabilities
|
|
121,113
|
|
130,487
|
Total
liabilities
|
|
4,178,723
|
|
4,231,352
|
Commitments and
contingencies
|
|
|
|
|
Stockholders'
equity:
|
|
|
|
|
Class A common
stock2
|
|
231
|
|
228
|
Class B-1 common
stock3
|
|
38
|
|
38
|
Class B-2 common
stock4
|
|
—
|
|
—
|
Preferred
stock5
|
|
—
|
|
—
|
Additional
paid-in-capital
|
|
2,229,582
|
|
2,152,342
|
(Accumulated deficit)
retained earnings
|
|
(1,047,243)
|
|
232,967
|
Accumulated other
comprehensive income (loss)
|
|
1,821
|
|
(4,098)
|
Total stockholders'
equity
|
|
1,184,429
|
|
2,381,477
|
Total liabilities and
stockholders' equity
|
|
$ 5,363,152
|
|
$ 6,612,829
|
|
|
(1)
|
Allowances for credit
losses are $1,806 and $952, respectively
|
(2)
|
Class A common stock,
$0.001 par value: Authorized - 1.0 billion shares; Issued and
outstanding - 231.2 million and 228.3 million shares,
respectively
|
(3)
|
Class B-1 common stock,
$0.001 par value: Authorized - 75.0 million shares; Issued and
outstanding - 37.8 million shares
|
(4)
|
Class B-2 common stock,
$0.000001 par value: Authorized - 75.0 million shares; Issued and
outstanding - 37.8 million shares
|
(5)
|
Preferred stock, $0.001
par value: Authorized - 25.0 million shares; Issued and outstanding
- none
|
PETCO HEALTH AND
WELLNESS COMPANY, INC.
|
CONSOLIDATED
STATEMENTS OF CASH FLOWS
|
(In
thousands)
|
(Unaudited and subject
to reclassification)
|
|
|
|
|
|
|
|
53 Weeks
Ended
|
|
52 Weeks
Ended
|
|
|
February 3,
2024
|
|
January 28,
2023
|
Cash flows from
operating activities:
|
|
|
|
|
Net (loss)
income
|
|
$(1,280,210)
|
|
$ 89,910
|
Adjustments to
reconcile net (loss) income to net cash provided by
operating activities:
|
|
|
|
|
Depreciation and
amortization
|
|
200,782
|
|
193,828
|
Amortization of debt
discounts and issuance costs
|
|
4,972
|
|
4,940
|
Provision for deferred
taxes
|
|
(53,549)
|
|
(893)
|
Equity-based
compensation expense
|
|
81,859
|
|
60,784
|
Impairments, write-offs
and losses on sale of fixed and other assets
|
|
2,833
|
|
1,992
|
Loss on extinguishment
and modification of debt
|
|
920
|
|
—
|
Income from equity
method investees
|
|
(16,188)
|
|
(12,976)
|
Amounts reclassified
out of accumulated other comprehensive income
|
|
(488)
|
|
168
|
Goodwill
impairment
|
|
1,222,524
|
|
—
|
Non-cash operating
lease costs
|
|
429,056
|
|
422,792
|
Other non-operating
(income) loss
|
|
(4,727)
|
|
12,667
|
Changes in assets and
liabilities:
|
|
|
|
|
Receivables
|
|
5,211
|
|
6,038
|
Merchandise
inventories
|
|
(32,072)
|
|
22,681
|
Prepaid expenses and
other assets
|
|
(8,009)
|
|
(5,933)
|
Accounts payable and
book overdrafts
|
|
103,919
|
|
(22,763)
|
Accrued salaries and
employee benefits
|
|
11,347
|
|
(51,427)
|
Accrued expenses and
other liabilities
|
|
(8,495)
|
|
13,616
|
Operating lease
liabilities
|
|
(446,981)
|
|
(386,259)
|
Other long-term
liabilities
|
|
3,015
|
|
(3,162)
|
Net
cash provided by operating activities
|
|
215,719
|
|
346,003
|
Cash flows from
investing activities:
|
|
|
|
|
Cash paid for fixed
assets
|
|
(225,598)
|
|
(278,020)
|
Cash paid for
acquisitions, net of cash acquired
|
|
(6,725)
|
|
(9,640)
|
Cash paid for interest
in veterinary joint venture
|
|
—
|
|
(35,000)
|
Proceeds from
investment
|
|
24,878
|
|
—
|
Proceeds from sale of
assets
|
|
—
|
|
2,336
|
Net
cash used in investing activities
|
|
(207,445)
|
|
(320,324)
|
Cash flows from
financing activities:
|
|
|
|
|
Borrowings under
long-term debt agreements
|
|
273,000
|
|
123,000
|
Repayments of long-term
debt
|
|
(348,000)
|
|
(140,000)
|
Payments for finance
lease liabilities
|
|
(5,925)
|
|
(5,083)
|
Proceeds from employee
stock purchase plan and stock option exercises
|
|
4,223
|
|
3,796
|
Tax withholdings on
stock-based awards
|
|
(8,650)
|
|
(15,555)
|
Net
cash used in financing activities
|
|
(85,352)
|
|
(33,842)
|
|
|
|
|
|
Net decrease in cash,
cash equivalents and restricted cash
|
|
(77,078)
|
|
(8,163)
|
Cash, cash equivalents
and restricted cash at beginning of period
|
|
213,727
|
|
221,890
|
Cash, cash equivalents
and restricted cash at end of period
|
|
$
136,649
|
|
$
213,727
|
NON-GAAP FINANCIAL MEASURES
The following information provides definitions and
reconciliations of the non-GAAP financial measures presented in
this earnings release to the most directly comparable financial
measures calculated and presented in accordance with generally
accepted accounting principles (GAAP). The company has provided
this non-GAAP financial information, which is not calculated or
presented in accordance with GAAP, as information supplemental and
in addition to the financial measures presented in this earnings
release that are calculated and presented in accordance with GAAP.
Such non-GAAP financial measures should not be considered superior
to, as a substitute for or alternative to, and should be considered
in conjunction with, the GAAP financial measures presented in this
earnings release. The non-GAAP financial measures in this earnings
release may differ from similarly titled measures used by other
companies.
The tables below reflect the calculation of Adjusted EBITDA,
Adjusted Net Income, and Adjusted EPS, as applicable, for the
fourteen and fifty-three weeks ended February 3, 2024 compared to the thirteen and
fifty-two weeks ended January 28,
2023, respectively.
Adjusted EBITDA and Trailing Twelve Month Adjusted
EBITDA
Adjusted EBITDA, including Trailing Twelve Month Adjusted
EBITDA, is considered a non-GAAP financial measure under the
Securities and Exchange Commission's (SEC) rules because it
excludes certain amounts included in net income calculated in
accordance with GAAP. Management believes that Adjusted EBITDA is a
meaningful measure to share with investors because it facilitates
comparison of the current period performance with that of the
comparable prior period. In addition, Adjusted EBITDA affords
investors a view of what management considers to be Petco's core
operating performance as well as the ability to make a more
informed assessment of such operating performance as compared with
that of the prior period. Please see the company's Annual Report on
Form 10-K for the fiscal year ended January
28, 2023 filed with the SEC on March
28, 2023 for additional information on Adjusted EBITDA.
(dollars in
thousands)
|
|
14 Weeks
Ended
|
|
13 Weeks
Ended
|
|
53 Weeks
Ended
|
|
52 Weeks
Ended
|
Reconciliation of
Net (Loss) Income Attributable to Class A and B-1
Common Stockholders to Adjusted
EBITDA
|
|
February 3,
2024
|
|
January 28,
2023
|
|
February 3,
2024
|
|
January 28,
2023
|
Net (loss) income
attributable to Class A and B-1 common stockholders
|
|
$
(22,575)
|
|
$
32,732
|
|
$
(1,280,210)
|
|
$
90,801
|
Add
(deduct):
|
|
|
|
|
|
|
|
|
Interest expense,
net
|
|
39,332
|
|
32,137
|
|
147,504
|
|
100,611
|
Income tax (benefit)
expense
|
|
(10,435)
|
|
14,548
|
|
(27,613)
|
|
35,347
|
Depreciation and
amortization
|
|
52,189
|
|
50,229
|
|
200,782
|
|
193,828
|
Income from equity
method investees
|
|
(6,156)
|
|
(5,155)
|
|
(16,188)
|
|
(12,976)
|
Loss on debt
extinguishment and modification
|
|
—
|
|
—
|
|
920
|
|
—
|
Goodwill
impairment
|
|
—
|
|
—
|
|
1,222,524
|
|
—
|
Losses (gains) on sale
of assets, impairments and write-offs
|
|
631
|
|
(307)
|
|
2,833
|
|
1,992
|
Equity-based
compensation expense
|
|
17,428
|
|
19,892
|
|
81,859
|
|
60,784
|
Other non-operating
loss (income)
|
|
—
|
|
3,298
|
|
(4,727)
|
|
12,667
|
Mexico joint venture
EBITDA (1)
|
|
11,759
|
|
9,265
|
|
38,226
|
|
29,584
|
Acquisition-related
integration costs (2)
|
|
—
|
|
627
|
|
—
|
|
15,314
|
Other costs
(3)
|
|
23,167
|
|
623
|
|
35,193
|
|
2,817
|
Adjusted
EBITDA
|
|
$
105,340
|
|
$
157,889
|
|
$
401,103
|
|
$
530,769
|
Net sales
|
|
$ 1,674,476
|
|
$ 1,577,959
|
|
$
6,255,284
|
|
$ 6,035,967
|
Net margin
(4)
|
|
(1.3 %)
|
|
2.1 %
|
|
(20.5 %)
|
|
1.5 %
|
Adjusted EBITDA
Margin
|
|
6.3 %
|
|
10.0 %
|
|
6.4 %
|
|
8.8 %
|
Adjusted Net Income and Adjusted EPS
Adjusted Net Income and Adjusted diluted Earnings Per Share
attributable to Petco common stockholders (Adjusted EPS) are
considered non-GAAP financial measures under the SEC's rules
because they exclude certain amounts included in the net income
attributable to Petco common stockholders and diluted earnings per
share attributable to Petco common stockholders calculated in
accordance with GAAP. Management believes that Adjusted Net Income
and Adjusted EPS are meaningful measures to share with investors
because they facilitate comparison of the current period
performance with that of the comparable prior period. In addition,
Adjusted Net Income and Adjusted EPS afford investors a view of
what management considers to be Petco's core earnings performance
as well as the ability to make a more informed assessment of such
earnings performance with that of the prior period.
(in thousands,
except per share amounts)
|
|
14 Weeks
Ended
|
|
13 Weeks
Ended
|
Reconciliation of
Diluted EPS to Adjusted EPS
|
|
February 3,
2024
|
|
January 28,
2023
|
|
|
Amount
|
|
Per
share
|
|
Amount
|
|
Per
share
|
Net (loss) income
attributable to common stockholders / diluted EPS
|
|
$
(22,575)
|
|
$
(0.08)
|
|
$
32,732
|
|
$
0.12
|
Add
(deduct):
|
|
|
|
|
|
|
|
|
Income tax (benefit)
expense
|
|
(10,435)
|
|
(0.04)
|
|
14,548
|
|
0.05
|
Loss on debt
extinguishment and modification
|
|
—
|
|
—
|
|
—
|
|
—
|
Goodwill
impairment
|
|
—
|
|
—
|
|
—
|
|
—
|
Losses (gains) on sale
of assets, impairments and write-offs
|
|
631
|
|
0.00
|
|
(307)
|
|
(0.00)
|
Equity-based
compensation expense
|
|
17,428
|
|
0.06
|
|
19,892
|
|
0.08
|
Other non-operating
loss
|
|
—
|
|
—
|
|
3,298
|
|
0.02
|
Acquisition-related
integration costs (2)
|
|
—
|
|
—
|
|
627
|
|
0.00
|
Other costs
(3)
|
|
23,167
|
|
0.09
|
|
623
|
|
0.00
|
Adjusted pre-tax income
/ diluted earnings per share
|
|
$
8,216
|
|
$
0.03
|
|
$
71,413
|
|
$
0.27
|
Income tax expense at
26% normalized tax rate
|
|
2,136
|
|
0.01
|
|
18,567
|
|
0.07
|
Adjusted Net Income
/ Adjusted EPS
|
|
$
6,080
|
|
$
0.02
|
|
$
52,846
|
|
$
0.20
|
(in thousands,
except per share amounts)
|
|
53 Weeks
Ended
|
|
52 Weeks
Ended
|
Reconciliation of
Diluted EPS to Adjusted EPS
|
|
February 3,
2024
|
|
January 28,
2023
|
|
|
Amount
|
|
Per
share
|
|
Amount
|
|
Per
share
|
Net (loss) income
attributable to common stockholders / diluted EPS
|
|
$
(1,280,210)
|
|
$
(4.78)
|
|
$
90,801
|
|
$
0.34
|
Add
(deduct):
|
|
|
|
|
|
|
|
|
Income tax (benefit)
expense
|
|
(27,613)
|
|
(0.10)
|
|
35,347
|
|
0.13
|
Loss on debt
extinguishment and modification
|
|
920
|
|
0.00
|
|
—
|
|
—
|
Goodwill
impairment
|
|
1,222,524
|
|
4.57
|
|
—
|
|
—
|
Losses on sale of
assets, impairments and write-offs
|
|
2,833
|
|
0.01
|
|
1,992
|
|
0.01
|
Equity-based
compensation expense
|
|
81,859
|
|
0.31
|
|
60,784
|
|
0.22
|
Other non-operating
(income) loss
|
|
(4,727)
|
|
(0.02)
|
|
12,667
|
|
0.05
|
Acquisition-related
integration costs (2)
|
|
—
|
|
—
|
|
15,314
|
|
0.06
|
Other costs
(3)
|
|
35,193
|
|
0.13
|
|
2,817
|
|
0.02
|
Adjusted pre-tax income
/ diluted earnings per share
|
|
$
30,779
|
|
$
0.12
|
|
$ 219,722
|
|
$
0.83
|
Income tax expense at
26% normalized tax rate
|
|
8,003
|
|
0.03
|
|
57,128
|
|
0.22
|
Adjusted Net Income
/ Adjusted EPS
|
|
$
22,776
|
|
$
0.09
|
|
$
162,594
|
|
$
0.61
|
Free Cash Flow
Free Cash Flow is a non-GAAP financial measure that is
calculated as net cash provided by operating activities less cash
paid for fixed assets. Management believes that Free Cash Flow,
which measures the ability to generate additional cash from
business operations, is an important financial measure for use in
evaluating the company's financial performance.
The table below reflects the calculation of Free Cash Flow for
the fourteen and fifty-three weeks ended February 3, 2024 compared to the thirteen and
fifty-two weeks ended January 28,
2023, respectively.
(in
thousands)
|
|
14 Weeks
Ended
|
|
13 Weeks
Ended
|
|
53 Weeks
Ended
|
|
52 Weeks
Ended
|
|
|
February 3,
2024
|
|
January 28,
2023
|
|
February 3,
2024
|
|
January 28,
2023
|
Net cash provided by
operating activities
|
|
$ 47,023
|
|
$
136,540
|
|
$
215,719
|
|
$
346,003
|
Cash paid for fixed
assets
|
|
(49,066)
|
|
(65,946)
|
|
(225,598)
|
|
(278,020)
|
Free Cash
Flow
|
|
$
(2,043)
|
|
$
70,594
|
|
$
(9,879)
|
|
$
67,983
|
Non-GAAP Financial Measures Footnotes
(1)
|
Mexico Joint Venture
EBITDA represents 50 percent of the entity's operating results for
all periods, as adjusted to reflect the results on a basis
comparable to Adjusted EBITDA. In the financial statements, this
joint venture is accounted for as an equity method investment and
reported net of depreciation and income taxes because such a
presentation would not reflect the adjustments made in the
calculation of Adjusted EBITDA, we include the 50 percent interest
in the company's Mexico joint venture on an Adjusted EBITDA basis
to ensure consistency. The table below presents a reconciliation of
Mexico joint venture net income to Mexico joint venture
EBITDA.
|
|
|
|
|
14 Weeks
Ended
|
|
13 Weeks
Ended
|
|
53 Weeks
Ended
|
|
52 Weeks
Ended
|
(in
thousands)
|
|
February 3,
2024
|
|
January 28,
2023
|
|
February 3,
2024
|
|
January 28,
2023
|
Net income
|
|
$ 12,311
|
|
$ 10,309
|
|
$ 32,375
|
|
$ 24,757
|
Depreciation
|
|
7,070
|
|
5,954
|
|
26,141
|
|
19,820
|
Income tax
expense
|
|
2,541
|
|
1,065
|
|
11,449
|
|
9,409
|
Foreign currency (gain)
loss
|
|
557
|
|
(253)
|
|
1,520
|
|
(268)
|
Interest expense,
net
|
|
1,039
|
|
1,455
|
|
4,966
|
|
5,449
|
EBITDA
|
|
$ 23,518
|
|
$ 18,530
|
|
$ 76,451
|
|
$ 59,167
|
50% of
EBITDA
|
|
$
11,759
|
|
$
9,265
|
|
$
38,226
|
|
$
29,584
|
|
|
(2)
|
Acquisition-related
integration costs include direct costs resulting from acquiring and
integrating businesses. These include third-party professional and
legal fees and other integration-related costs that would not have
otherwise been incurred as part of the company's
operations.
|
|
|
(3)
|
Other costs include, as
incurred: restructuring costs and restructuring-related severance
costs; legal reserves associated with significant, non-ordinary
course legal or regulatory matters; and costs related to certain
significant strategic transactions.
|
|
|
(4)
|
We define net margin as
net income attributable to Class A and B-1 common stockholders
divided by net sales and Adjusted EBITDA margin as Adjusted EBITDA
divided by net sales.
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/petco-health--wellness-company-inc-reports-fourth-quarter-and-full-year-2023-earnings-302087395.html
SOURCE Petco - Investor Relations